Data as of Oct 24
| +0.25 / +2.13%|
The 3 analysts offering 12-month price forecasts for ADMA Biologics Inc have a median target of 16.00, with a high estimate of 16.00 and a low estimate of 15.00. The median estimate represents a +33.33% increase from the last price of 12.00.
The current consensus among 3 polled investment analysts is to Buy stock in ADMA Biologics Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.